News from epivax, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 30, 2014, 11:17 ET

Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics

Chugai Pharmaceutical Co., Ltd. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's...

Jul 08, 2014, 10:44 ET

New Immunogenicity Analysis Tool Emerges from Dartmouth-EpiVax-URI Collaboration "In Silico" Host Cell Protein for Protein Therapeutics

A Public-private partnership resulted in the development of a new web-based tool that will help manufacturers of protein-based therapeutics improve...

Dec 03, 2013, 06:00 ET
EpiVax is an immunology company. We develop and employ extensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to predicting, and reducing, the immunogenicity of protein therapeutics and designed more effective (and safer) vaccines. www.EpiVax.com. (PRNewsFoto/EpiVax, Inc.)

Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A

 Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement....

Apr 24, 2013, 09:00 ET
EpiVax is an immunology company. We develop and employ extensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to predicting, and reducing, the immunogenicity of protein therapeutics and designed more effective (and safer) vaccines. www.EpiVax.com. (PRNewsFoto/EpiVax, Inc.)

BioAtla Combines EpiVax's Immunogenicity Screening Into Their Express Humanization™ Platform

 Full article – http://bit.ly/EpiAtla13 EpiVax Inc., an unique immunology company with a strong focus on immunogenicity mitigation and...

Apr 13, 2013, 09:00 ET
EpiVax is an immunology company. We develop and employ extensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to predicting, and reducing, the immunogenicity of protein therapeutics and designed more effective (and safer) vaccines. www.EpiVax.com. (PRNewsFoto/EpiVax, Inc.)

Why H7N9 (Shanghai 2013) is the new stealth virus and what we can do about it.

 Full Story – http://bit.ly/H7N9EpiVax The H7N9 emerging from China is a stealth virus. State of the art bioinforamatics tools...

Feb 12, 2013, 09:00 ET
EpiVax is an immunology company. We develop and employ extensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to predicting, and reducing, the immunogenicity of protein therapeutics and designed more effective (and safer) vaccines. www.EpiVax.com. (PRNewsFoto/EpiVax, Inc.)

EpiVax-Novozymes Tregitope-Albumin Fusion Moves 'Paradigm-Shifting' Treatment for Diabetes Closer to Clinical Trials

 EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to...

Nov 16, 2012, 14:30 ET
EpiVax is an immunology company. We develop and employ extensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to predicting, and reducing, the immunogenicity of protein therapeutics and designed more effective (and safer) vaccines. www.EpiVax.com. (PRNewsFoto/EpiVax, Inc.)

Funding for Orphan Disease Indication Will Compare EpiVax's Tregitope with IVIG

Full Article Here Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to...

Nov 26, 2008, 12:00 ET

EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery

EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of...